| Literature DB >> 36013133 |
Abstract
The bilateral axillo-breast approach (BABA) for robot-assisted thyroidectomy has some advantages over other minimally invasive thyroidectomies. However, some people do not consider this as a minimally invasive thyroidectomy because of the wider surgical skin flap. Thus, we devised mini-flap BABA robot-assisted thyroidectomy and analyzed the postoperative outcomes. The clinical records of 44 patients undergoing BABA robot-assisted thyroidectomy using a conventional flap or mini-flap were evaluated retrospectively. There were no significant group differences in clinicopathological characteristics. The operating and flap making times were shorter in the mini-flap group (206.18 ± 31.09 vs. 178.90 ± 34.43 min, p = 0.009; 38.85 ± 2.73 vs. 32.21 ± 8.62 min, p = 0.003, respectively). The total drainage amount was smaller in the mini-flap group (196.57 ± 81.40 vs. 150.74 ± 40.80 mL, p = 0.027). The numeric rating scale score and number of analgesics were lower at 2 h postoperatively in the mini-flap group (5.52 ± 0.87 vs. 4.57 ± 1.31, p = 0.006; 0.95 ± 0.22 vs. 0.65 ± 0.49, p = 0.012, respectively). There was no significant group difference in immediate oncological outcomes (p = 1.000). Mini-flap BABA robot-assisted thyroidectomy minimized the surgical flap and improved surgical outcomes. Therefore, it is a form of minimally invasive thyroidectomy. However, long-term follow-up of oncological outcomes is needed.Entities:
Keywords: bilateral axillo-breast approach (BABA); mini-flap; minimally invasive surgery; minimally invasive thyroidectomy; robot-assisted thyroidectomy
Year: 2022 PMID: 36013133 PMCID: PMC9410211 DOI: 10.3390/jcm11164894
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1Guidelines for (a) conventional BABA robot-assisted thyroidectomy and (b,c) mini-flap BABA robot-assisted thyroidectomy.
Figure 2Endoscopic view after making the flaps. (a,c) Conventional and (b,d) mini-flap. SCM: sternocleidomastoid muscle.
Clinicopathological characteristics of the patients.
| Group | ||||
|---|---|---|---|---|
| Overall | Conventional | Mini-Flap | ||
| Age, years | 40.07 ± 12.01 | 41.19 ± 12.04 | 39.04 ± 12.33 | 0.721 |
| Sex | 1.000 | |||
| Male | 5 (11.4%) | 2 (9.5%) | 3 (13.0%) | |
| Female | 39 (88.6%) | 19 (90.5%) | 20 (87.0%) | |
| BMI (kg/m2) | 24.11 ± 4.22 | 24.07 ± 2.88 | 24.15 ± 5.23 | 0.951 |
| Extent of surgery | 1.000 | |||
| Total thyroidectomy | 7 (15.9%) | 3 (14.3%) | 4 (17.4%) | |
| Unilateral thyroidectomy | 37 (84.1%) | 18 (85.7%) | 19 (82.6%) | |
| CND | 0.709 | |||
| Not performed | 7 (15.9%) | 2 (9.5%) | 5 (21.7%) | |
| Unilateral | 36 (81.8%) | 18 (85.7%) | 18 (78.3%) | |
| Bilateral | 1 (2.3%) | 1 (4.8%) | 0 | |
| Nodes retrieved | 5.60 ± 3.97 | 6.81 ± 4.39 | 4.45 ± 3.20 | 0.050 |
| Metastatic LN | 1.14 ± 2.04 | 1.38 ± 2.58 | 0.91 ± 1.38 | 0.455 |
| Tumor diameter (cm) | 1.05 ± 0.75 | 0.88 ± 0.60 | 1.21 ± 0.85 | 0.149 |
| Pathologic diagnosis | 1.000 | |||
| PTC | 34 (77.3%) | 17 (81.0%) | 17 (73.9%) | |
| HCC | 1 (2.3%) | 0 | 1(4.3%) | |
| Benign | 9 (20.5%) | 4 (19.0%) | 5 (21.7%) | |
| ETE | 1.000 | |||
| Yes | 1 (2.3%) | 0 | 1 (4.3%) | |
| No | 43 (97.7%) | 21 (100.0%) | 22 (95.7%) | |
| Thyroiditis | 0.042 | |||
| Yes | 12 (27.3%) | 9 (42.9%) | 3 (13.0%) | |
| No | 32 (72.7%) | 12 (57.1%) | 20 (87.0%) | |
| Pathological T stage * | 1.000 | |||
| 1a | 26 (74.3%) | 13 (76.5%) | 13 (72.2%) | |
| 1b | 8 (22.9%) | 4 (23.5%) | 4 (22.2%) | |
| 3b | 1 (2.9%) | 0 | 1 (5.6%) | |
| Pathological N stage * | 0.845 | |||
| 0 | 15 (42.9%) | 7 (41.2%) | 8 (44.4%) | |
| 1a | 20 (57.1%) | 10 (58.8%) | 10 (55.6%) | |
| AJCC (8th edition) stage * | 1.000 | |||
| I | 33 (94.3%) | 16 (94.1%) | 17 (94.4%) | |
| II | 2 (5.7%) | 1 (5.9%) | 1 (5.6%) | |
* Available for the 35 patients with malignancy. Values are expressed as mean ± standard deviation or numbers (%). BMI, body mass index; CND, central node dissection; PTC, papillary thyroid cancer; HCC, Hürthle cell carcinoma; ETE, extrathyroidal extension.
Group comparison of clinical outcomes.
| Group | ||||
|---|---|---|---|---|
| Overall | Conventional | Mini-Flap | ||
| Operating time (min) | 191.92 ± 35.62 | 206.18 ± 31.09 | 178.90 ± 34.43 | 0.009 |
| Flap-making time (min) | 33.75 ± 8.12 | 38.85 ± 2.73 | 32.21 ± 8.62 | 0.003 |
| Estimated blood loss (mL) | 98.14 ± 48.89 | 92.05 ± 41.67 | 103.70 ± 55.00 | 0.436 |
| Total drainage (mL) | 172.61 ± 66.85 | 196.57 ± 81.40 | 150.74 ± 40.80 | 0.027 |
| Hospital stay (days) | 4.66 ± 1.18 | 4.86 ± 1.24 | 4.48 ± 1.12 | 0.293 |
Values are expressed as mean ± standard deviation or numbers (%).
Group comparison of pain parameters.
| Group | |||
|---|---|---|---|
| Conventional | Mini-Flap | ||
| Numeric rating scale score | |||
| Postoperative 2 h | 5.52 ± 0.87 | 4.57 ± 1.31 | 0.006 |
| Postoperative 24 h | 2.81 ± 0.40 | 3.00 ± 1.09 | 0.440 |
| Postoperative 48 h | 2.76 ± 0.44 | 2.87 ± 0.87 | 0.612 |
| Postoperative 72 h | 2.67 ± 0.48 | 2.39 ± 0.78 | 0.172 |
| Number of analgesics | |||
| Postoperative 2 h | 0.95 ± 0.22 | 0.65 ± 0.49 | 0.012 |
| Postoperative 24 h | 0.29 ± 0.56 | 0.48 ± 0.59 | 0.276 |
| Postoperative 48 h | 0.48 ± 0.98 | 0.30 ± 0.77 | 0.518 |
| Postoperative 72 h | 0.00 ± 0.00 | 0.09 ± 0.29 | 0.162 |
Values are expressed as mean ± standard deviation or numbers (%).
Group comparison of surgical outcomes.
| Group | ||||
|---|---|---|---|---|
| Overall | Conventional | Mini-Flap | ||
| Postoperative lowest iPTH (pg/mL) | 38.81 ± 18.40 | 39.98 ± 17.89 | 37.75 ± 19.20 | 0.693 |
| Postoperative hypoparathyroidism | 1.000 | |||
| No | 41 (93.2%) | 20 (95.2%) | 21 (91.3%) | |
| Transient | 3 (6.8%) | 1 (4.8%) | 2 (8.7%) | |
| Permanent | 0 | 0 | 0 | |
| Postoperative vocal cord palsy | 0.599 | |||
| No | 41 (93.2%) | 19 (90.5%) | 22 (95.7%) | |
| Transient | 3 (6.8%) | 2 (9.5%) | 1 (4.3%) | |
| Permanent | 0 | 0 | 0 | |
| Other complications | 0 | 0 | 0 | |
Values are expressed as mean ± standard deviation or numbers (%). iPTH, intact parathyroid hormone.
Group comparison of immediate-oncological outcomes.
| Group | ||||
|---|---|---|---|---|
| Overall | Conventional | Mini-Flap | ||
| Response to therapy | 1.000 | |||
| Excellent | 31 (88.6%) | 16 (94.1%) | 15 (83.3%) | |
| Indeterminate | 3 (8.6%) | 1 (5.9%) | 2 (11.1%) | |
| Biochemically incomplete | 1 (2.9%) | 0 | 1 (5.6%) | |
| Structurally incomplete | 0 | 0 | 0 | |
Values are expressed as the mean ± standard deviation or numbers (%).